Granzyme B production of CD8 T cells is reduced by anti-CD132 treatment. (A) Survival of BALB/c mice which received BM and CD8 T cells (1 × 10⁶) after TBI. Pooled survival of 2 experiments is shown. The group receiving anti-CD132 mAb survived significantly longer than the group receiving the isotype control (P < .0001). (B) Survival of BALB/c mice which received BM and CD4 T cells (7.5 × 10⁵) after TBI. The difference in survival between the anti-CD132 mAb and isotype groups was not significant at the 95% confidence level. (C) Spleens were removed from transplanted mice on day 7 after BMT and analyzed for the percentage of CD8⁺ cells. Data are shown for 12 animals per group. (D) Granzyme B levels were analyzed in CD8 cells. Data are pooled from 2 experiments representing 12 animals per group (*P < .05). (E) GVHD histopathology scores for liver, small intestine, and large intestine are displayed. Mice underwent allo-HCT (BALB.B into C57BL/6) and treatment with anti-CD132 or unspecific IgG. Allo-HCT recipients were sacrificed on day 12 after transplantation (*P < .05). (F) Survival of mice undergoing allo-HCT (day 0) and transfer of conventional T cells (day 2) alone or in combination with purified CD4⁺/CD25⁺ Treg (day 0) and anti-CD132 antibody, or Treg (day 0) and unspecific IgG treatment. No significant difference was observed between the groups receiving Treg cells, independent of CD132 treatment.